Biomarkers in Autoimmune Disease of Nervous System

Sponsor
Tongji Hospital
Study ID
NCT06502015
Status
Recruiting
Apply to this trial

Conditions

  • Acute Disseminated Encephalomyelitis
  • Autoimmune Diseases
  • Autoimmune Diseases of the Nervous System
  • Autoimmune Encephalitis
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  • Guillain-Barre Syndrome
  • Idiopathic Inflammatory Myopathies
  • Multiple Sclerosis
  • Myasthenia Gravis
  • Neuromyelitis Optica Spectrum Disorder
  • Stiff-Person Syndrome

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • biomaker levels — DIAGNOSTIC_TEST
    this study will discover and validate novel biomarkers (including blood, feces, bone marrow and lymph nodes etc al) of various neurological autoimmune diseases

Study Details

Neurological autoimmune diseases are a group of disorders characterized by the abnormal immune response attacking the nervous system, including the brain, spinal cord and peripheral nerves. These diseases exhibit high heterogeneity, diverse clinical presentations, and are challenging to diagnose and manage due to a lack of effective treatments. In this study, the investigators will recruit eight kinds of autoimmune diseases of nervous system including Neuromyelitis Optica Spectrum Disorder (NMOSD), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), idiopathic inflammatory myopathy (IIM), and multiple sclerosis (MS), autoimmune encephalitis (AE), Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD). Through this study, the investigators aim to discover biomarkers with high sensitivity, specificity, and stability, which can support early diagnosis, disease monitoring, and personalized treatment for neurological autoimmune diseases, thereby improving the quality of life and prognosis for patients.

Key Dates

First listed
Jul 15, 2024
Start date
Jul 31, 2024
Status verified
Nov 2024
Primary completion
Jul 31, 2027
Completion
Jul 31, 2027

Study Design

Enrollment
50,000 participants (estimated)

Arms

  • Arm: autoimmune disease
    clinical diagnosis with autoimmune disease of central nervous system
  • Arm: health control
    age- and sex-matched control individuals

Primary Outcome Measure

All-cause mortality [ Time Frame: 10 years ]

Central Contacts

Find similar trials

Nationwide
Multiple sclerosis trialsNeurology trialsBrain disorders trialsAutoimmune disease trials

Related Studies